A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D for Metastatic Breast Cancer

NCT00190489 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

450

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Neoplasm Metastasis

Interventions

DRUG: AC (ADM 40mg/m2+CPA 500mg/m2) q21 days x 6 cycles
DRUG: Docetaxel 60mg/m2 every 21 days for 6 cycles
DRUG: AC and Docetaxel 60mg/m2 alternately q21 days for 6 cycles

Sponsor

Japan Clinical Oncology Group

Collaborators

[object Object]